Epiduo Forte is an acne treatment owned by Galderma Labs. First authorized for market use on 15 July, 2015, the drug's active ingredients are Adapalene and Benzoyl Peroxide.
The generic version of Epiduo Forte is anticipated to be released after 12 March, 2023. This is due to the expiration of the last patent held by Galderma Labs, specifically US8729127 titled 'Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders'.
Epiduo Forte is primarily used for the treatment of acne. Its effectiveness is due to the strategic combination of Adapalene and Benzoyl Peroxide, which work together to combat acne lesions.
Epiduo Forte holds a total of 9 patents, all of which are now expired. The last active patent, US8729127, is set to expire on 12 March, 2023, paving the way for the release of generic Epiduo Forte. Below are the details of the patents: